PCN227 A COMPARISON BETWEEN ICER (US) AND NICE (UK) HEALTH TECHNOLOGY ASSESSMENT (HTA) DECISION-MAKING FOR PD-1 INHIBITORS IN NON-SMALL-CELL LUNG CARCINOMA (NSCLC): OTHER BENEFITS AND CONTEXTUAL CONSIDERATIONS.